Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz

Lenz Therapeutics is absorbing sickle-cell-focused Graphite Bio in a reverse merger that will see the combined company reemerge with a focus on vision loss and $225 million in cash on hand at close.